Bradley J Stish1, Safia K Ahmed1, Peter S Rose2, Carola A Arndt3, Nadia N Laack1. 1. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 2. Division of Orthopedic Oncology, Mayo Clinic, Rochester, Minnesota. 3. Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Little data exist regarding long-term functional and quality of life (QOL) outcomes for survivors of Ewing sarcoma (ES). Specifically, there are few reports assessing the impact of patient characteristics and local therapy modalities on patient-reported outcomes (PRO). PROCEDURE: Long-term survivors of ES treated between 1977 and 2009 completed self-assessed functional and QOL surveys, using the Toronto Extremity Salvage Score (TESS) and PEDSQL 4.0 generic core instruments, respectively. Statistical analyses were performed to correlate these outcomes to clinical presentations and treatment regimens. RESULTS: Subjects (n = 74) with a mean duration from diagnosis of 17.8 years completed the survey. Mean TESS and PEDSQL total scores for the entire cohort were 93.0 ± 10.3 and 81.6 ± 18.0, respectively. No significant differences were appreciated between adult and pediatric patients, although increasing age was associated with lower functional scores (P = 0.04). Mean PEDSQL total scores were significantly lower for female patients (74.6 ± 19.7) compared to males (85.7 ± 15.7) (P = 0.01). Mild to moderate disability was reported by 32% of respondents and was associated with lower TESS and PEDSQL scores. Local control modality did not significantly affect functional and QOL scores. Patients with pelvic tumors had significantly lower TESS scores compared to those with nonpelvic tumors (P = 0.04), especially amongst patients treated with both surgery and radiation. CONCLUSIONS: Although many survivors of ES report excellent functional and QOL outcomes, a significant number report long-term disability and impairments. Older patients, females, and those with pelvic primary tumors appear at the greatest risk for long-term decrements and may benefit from early therapeutic interventions.
BACKGROUND: Little data exist regarding long-term functional and quality of life (QOL) outcomes for survivors of Ewing sarcoma (ES). Specifically, there are few reports assessing the impact of patient characteristics and local therapy modalities on patient-reported outcomes (PRO). PROCEDURE: Long-term survivors of ES treated between 1977 and 2009 completed self-assessed functional and QOL surveys, using the Toronto Extremity Salvage Score (TESS) and PEDSQL 4.0 generic core instruments, respectively. Statistical analyses were performed to correlate these outcomes to clinical presentations and treatment regimens. RESULTS: Subjects (n = 74) with a mean duration from diagnosis of 17.8 years completed the survey. Mean TESS and PEDSQL total scores for the entire cohort were 93.0 ± 10.3 and 81.6 ± 18.0, respectively. No significant differences were appreciated between adult and pediatric patients, although increasing age was associated with lower functional scores (P = 0.04). Mean PEDSQL total scores were significantly lower for female patients (74.6 ± 19.7) compared to males (85.7 ± 15.7) (P = 0.01). Mild to moderate disability was reported by 32% of respondents and was associated with lower TESS and PEDSQL scores. Local control modality did not significantly affect functional and QOL scores. Patients with pelvic tumors had significantly lower TESS scores compared to those with nonpelvic tumors (P = 0.04), especially amongst patients treated with both surgery and radiation. CONCLUSIONS: Although many survivors of ES report excellent functional and QOL outcomes, a significant number report long-term disability and impairments. Older patients, females, and those with pelvic primary tumors appear at the greatest risk for long-term decrements and may benefit from early therapeutic interventions.
Authors: M E Nesbit; E A Gehan; E O Burgert; T J Vietti; A Cangir; M Tefft; R Evans; P Thomas; F B Askin; J M Kissane Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544
Authors: Lonnie K Zeltzer; Qian Lu; Wendy Leisenring; Jennie C I Tsao; Christopher Recklitis; Gregory Armstrong; Ann C Mertens; Leslie L Robison; Kirsten K Ness Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-02 Impact factor: 4.254
Authors: R Nagarajan; D R Clohisy; J P Neglia; Y Yasui; P A Mitby; C Sklar; J Z Finklestein; M Greenberg; G H Reaman; L Zeltzer; L L Robison Journal: Br J Cancer Date: 2004-11-29 Impact factor: 7.640
Authors: Janine Piscione; Wendy Barden; Janie Barry; Alexandra Malkin; Trisha Roy; Tyki Sueyoshi; Karen Mazil; Steven Salomon; Firas Dandachli; Anthony Griffin; Hugo Saint-Yves; Pina Giuliano; Abha Gupta; Peter Ferguson; Katrin Scheinemann; Michelle Ghert; Robert E Turcotte; Lucie Lafay-Cousin; Joel Werier; Caron Strahlendorf; Marc Isler; Sophie Mottard; Samina Afzal; Megan E Anderson; Sevan Hopyan Journal: Clin Orthop Relat Res Date: 2019-09 Impact factor: 4.176
Authors: Neyssa M Marina; Qi Liu; Sarah S Donaldson; Charles A Sklar; Gregory T Armstrong; Kevin C Oeffinger; Wendy M Leisenring; Jill P Ginsberg; Tara O Henderson; Joseph P Neglia; Marilyn A Stovall; Yutaka Yasui; R Lor Randall; David S Geller; Leslie L Robison; Kirsten K Ness Journal: Cancer Date: 2017-02-21 Impact factor: 6.860
Authors: Israel Fernandez-Pineda; M M Hudson; A S Pappo; M W Bishop; J L Klosky; T M Brinkman; D K Srivastava; M D Neel; B N Rao; A M Davidoff; K R Krull; D A Mulrooney; L L Robison; K K Ness Journal: J Cancer Surviv Date: 2016-06-04 Impact factor: 4.442
Authors: Safia K Ahmed; R Lor Randall; Steven G DuBois; William S Harmsen; Mark Krailo; Karen J Marcus; Katherine A Janeway; David S Geller; Joel I Sorger; Richard B Womer; Linda Granowetter; Holcombe E Grier; Richard G Gorlick; Nadia N I Laack Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-24 Impact factor: 7.038
Authors: Najat C Daw; Nadia N Laack; Elizabeth J McIlvaine; Mark Krailo; Richard B Womer; Linda Granowetter; Holcombe E Grier; Neyssa M Marina; Mark L Bernstein; Mark C Gebhardt; Karen J Marcus; Shailesh M Advani; John H Healey; George D Letson; Richard G Gorlick; R Lor Randall Journal: Ann Surg Oncol Date: 2016-05-23 Impact factor: 5.344
Authors: Lesley Storey; Lorna A Fern; Ana Martins; Mary Wells; Lindsey Bennister; Craig Gerrand; Maria Onasanya; Jeremy S Whelan; Rachael Windsor; Julie Woodford; Rachel M Taylor Journal: Sarcoma Date: 2019-02-17